Microarray and sequencing specialist Illumina has entered the consumer genomics game with a DTC personal genome sequencing service. It's distancing itself from regulators by partnering with others to handle any secondary data interpretation and dialog with customers, but cautious or not, by reaching out directly to the public, the move does turn on its head the traditional notion of first developing a technology tool for research, then moving on to more regimented clinical applications.

Data from the first 275 patients in the trial are promising, but outside experts say they are wary of another hasty Emergency Use Authorization.

European Commission medtech news all but dried up in September. But the UK’s Brexit news and implications for medtech has given EU and UK medtech stakeholders enough to ponder.